Allogene Therapeutics, Inc.

ALLO • Biotechnology

$1.97

▼ -0.01 (-0.51%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$651.28M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.26Healthy liquidity · 7.93Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:11 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$1.97

Change-0.51%

Shares Out328.93M

Market Cap$651.28M

Enterprise Value$389.03M

52W Range0.99 - 4.46

Beta0.47

P/E-3.94

P/B1.49

P/FCF-6.35

EV/EBITDA-2.32

EV/FCF-3.79

Price$1.97

Change-0.51%

Shares Out328.93M

Market Cap$651.28M

Enterprise Value$389.03M

52W Range0.99 - 4.46

Beta0.47

P/E-3.94

P/B1.49

P/FCF-6.35

EV/EBITDA-2.32

EV/FCF-3.79

Earnings Yield-25.41%

FCF Yield-15.75%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.26

Current Ratio7.93

Quick Ratio7.93

Target$6.43

Target Upside226.40%

Target Median$6.43

Target Range3.85 - 9.00

Volume6.32M

Avg Volume9.90M

EPS Surprise0.01

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

95/100

Why this score▼

Manageable debt level · 0.26Healthy liquidity · 7.93Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

ALLO

Analyst sentiment

Based on 30 analyst votes · 2026-09-04

80/100

Bullish

Hold

Bearish

Price Target

2026-08-14

Low

$3.85

Mean

$6.43

Median

$6.42

High

$9.00

Company Overview

IPO: 10/11/2018

Industry: Biotechnology

P/B i: 1.49

Debt / Equity i: 0.26

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.26

Current Ratio: 7.93

Quick Ratio: 7.93

Status: Good

Insider Transactions

Recent executive and insider activity

Roberts Zachary

Transaction: 07/01/2026

BUY

Change

+134,530

Price

Not reported

Filing

07/06/2026

Type

BUY

Roberts Zachary

Transaction: 07/01/2026

BUY

Change

+476,190

Price

$2.11

Filing

07/06/2026

Type

BUY

Barrett Elizabeth A.

Transaction: 06/18/2026

BUY

Change

+95,400

Price

Not reported

Filing

06/23/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Roberts Zachary	BUY	+134,530	Not reported	07/01/2026	07/06/2026
Roberts Zachary	BUY	+476,190	$2.11	07/01/2026	07/06/2026
Barrett Elizabeth A.	BUY	+95,400	Not reported	06/18/2026	06/23/2026
Humer Franz B	BUY	+95,400	Not reported	06/18/2026	06/23/2026
WITTE OWEN N.	BUY	+95,400	Not reported	06/18/2026	06/23/2026
SATO VICKI L	BUY	+95,400	Not reported	06/18/2026	06/23/2026
Mayo Stephen	BUY	+144,400	$2.00	06/18/2026	06/23/2026
MESSEMER DEBORAH M.	BUY	+95,400	Not reported	06/18/2026	06/23/2026
Kazam Joshua A	SELL	-47,700	Not reported	06/18/2026	06/23/2026
Kazam Joshua A	BUY	+47,700	Not reported	06/18/2026	06/23/2026
Yoshiyama Annie	SELL	-9,586	$2.31	04/21/2026	04/23/2026
Beneski Benjamin Machinas	SELL	-2,867	$2.50	03/31/2026	04/02/2026
Chang David D	SELL	-47,763	$2.47	03/16/2026	03/18/2026
Beneski Benjamin Machinas	SELL	-4,835	$2.47	03/16/2026	03/18/2026
Beneski Benjamin Machinas	SELL	-7,132	$2.60	03/02/2026	03/04/2026
Belldegrun Arie	BUY	+263,033	Not reported	02/02/2026	02/04/2026
Belldegrun Arie	BUY	+929,913	$1.87	02/02/2026	02/04/2026
Roberts Zachary	BUY	+203,307	Not reported	02/02/2026	02/04/2026
Roberts Zachary	SELL	-35,700	$1.77	02/02/2026	02/04/2026
Roberts Zachary	BUY	+718,763	$1.87	02/02/2026	02/04/2026

About the Company

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.

Source - link

Peers

ACHV AVIR CABA CRBU EDIT HUMA IMMP KYTX VNDA VYGR

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026.

GlobeNewsWire

Deutsche Bank AG Purchases Shares of 281,949 Allogene Therapeutics, Inc. $ALLO

Deutsche Bank AG bought a new stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) in the quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 281,949 shares of the company's stock, valued at approximately $586,000. Deutsche Bank AG owned about 0.08% of Allogene

Defense World

Connor Clark & Lunn Investment Management Ltd. Invests $671,000 in Allogene Therapeutics, Inc. $ALLO

Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) during the quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 322,827 shares of the company's stock, valued at approximately $671,000. Connor Clark

Defense World

Allogene Therapeutics Announces Participation in September Investor Conference

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September.

GlobeNewsWire

Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way?

Cema-cel produced MRD clearance in 58.3% of treated patients versus 16.7% under observation. The 97.7% median ctDNA reduction by day 45 shows substantial early biological activity. FDA RMAT and Fast Track designations support the development strategy but do not prove durable efficacy.

Seeking Alpha

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-13	-0.19	-0.18	0.01
2026-03-12	-0.25	-0.17	0.08
2025-11-06	-0.23	-0.19	0.04
2025-08-13	-0.28	-0.23	0.05
2025-05-13	-0.28	-0.28	0
2025-03-13	-0.34	-0.28	0.06
2024-11-07	-0.34	-0.27	0.07
2024-08-07	-0.35	-0.32	0.03
2024-05-13	-0.38	-0.38	0
2024-03-14	-0.47	-0.43	0.04
2023-11-02	-0.53	-0.37	0.16
2023-08-02	-0.59	-0.53	0.06